Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AMLI fusion transcript

Genes Chromosomes and Cancer

Volumn 26, Issue 4, 1999, Pages 355-365

  Pallisgaard, Niels ^a   Clausen, Niels ^a   Schrøder, Henrik ^a   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; ARTICLE; CANCER CELL; CHILD; CLINICAL ARTICLE; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BETA 2-MICROGLOBULIN; BONE MARROW; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 21; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA PRIMERS; DNA, NEOPLASM; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TRANSLOCATION, GENETIC;

TRIXIS;

EID: 0032724360     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199912)26:4<355::AID-GCC10>3.0.CO;2-3     Document Type: Article

References (28)

1. Agape P, Gerard B, Cave H, Devaux I, Vilmer E, Lecomte MC, Grandchamp B. 1997. Analysis of ETV6 and ETV6-AML1 proteins in acute lymphoblastic leukaemia. Br J Haematol 98:234-239.
2. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H, et al. 1994. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 343:196-200.
3. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E. 1998. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia: European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 339:591-598.
4. Cayuela JM, Baruchel A, Orange C, Madani A, Auclerc MF, Daniel MT, Schaison G, Sigaux F. 1996. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 88:302-308.
5. Cross NC. 1995. Quantitative PCR techniques and applications. Br J Haematol 89:693-697.
6. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. 1997. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 90:4933-4937.
7. Gibson UE, Held CA, Williams PM. 1996. A novel method for real time quantitative RT-PCR. Genome Res 6:995-1001.
8. Heid CA, Stevens J, Livak KJ, Williams PM. 1996. Real time quantitative PCR. Genome Res 6:986-994.
9. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. 1996. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 87:1549-1555.
10. Look AT. 1997. Oncogenic transcription factors in the human acute leukemias. Science 278:1059-1064.
11. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F. 1997. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy: Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 90:1014-1021.
12. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. 1998. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 12:1482-1489.
13. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, De Witte T. 1998. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 102:768-774.
14. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. 1997. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 24:17-31.
15. Muto A, Mori S, Matsushita H, Awaya N, Ueno H, Takayama N, Okamoto S, Kizaki M, Ikeda Y. 1996. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitivc PCR assay. Br J Haematol 95:85-94.
16. Nakao M, Yokota S, Horiike S, Taniwaki M, Kashima K, Sonoda Y, Koizumi S, Takaue Y, Matsushita T, Fujimoto T, Misawa S. 1996. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia 10:1463-1470.
17. Norgaard JM, Bukh A, Langkjer ST, Clausen N, Palshof T, Hokland P. 1998. MDR1 gene expression and drug resistance of AML cells. Br J Haematol 100:534-540.
18. Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P. 1998. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 92:574-588.
19. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ. 1998. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12:2006-2014.
20. Radich J, Ladne P, Gooley T. 1995. Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT. Biol Blood Marrow Transplant 1:24-31.
21. Romana SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard OA. 1995. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 85:3662-3670.
22. Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM, Pui CH, Downing JR, Behm FG. 1997. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood 89:1143-1146.
23. Satake N, Kobayashi H, Tsunematsu Y, Kawasaki H, Horikoshi Y, Koizumi S, Kaneko Y. 1997. Minimal residual disease with TEL-AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21). Br J Haematol 97:607-611.
24. Seale JR, Varma S, Swirsky DM, Pandolfi PP, Goldman JM, Cross NC. 1996. Quantification of PML-RAR alpha transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon. Br J Haematol 95:95-101.
25. Seeger K, Adams HP, Buchwald D, Beyermann B, Kremens B, Niemeyer C, Ritter J, Schwabe D, Harms D, Schrappe M, Henze G. 1998. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia: the Berlin-Frankfurt-Munster Study Group. Blood 91:1716-1722.
26. Uphoff CC, MacLeod RA, Denkmann SA, Golub TR, Borkhardt A, Janssen JW, Drexler HG. 1997. Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines. Leukemia 11:441-447.
27. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR. 1998. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731-1738.
28. Waha A, Watzka M, Koch A, Pietsch T, Przkora R, Peters N, Wiestler OD, von Deimling A. 1998. A rapid and sensitive protocol for competitive reverse transcriptase (cRT) PCR analysis of cellular genes. Brain Pathol 8:13-18.